Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172732 | 0.80 | GRM2 (0.35) | GRM2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL12407048 | 0.78 | CACNA1G (0.37) | GRM2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL3798888 | 0.75 | KDM4A (0.40) | GRM2CACNA1BCACNA1C | |
| SCHEMBL26086914 | 0.74 | GRM2 (0.39) | GRM2SSTR4HDAC1HDAC8HDAC6 | |
| SCHEMBL2552257 | 0.74 | HDAC1 (0.30) | HDAC1HDAC8HDAC6 | |
| SCHEMBL28350803 | 0.74 | SSTR4 (0.39) | GRM2SSTR4HDAC1 | |
| SCHEMBL2552259 | 0.73 | HTT (0.50) | — | |
| SCHEMBL2713539 | 0.70 | CACNA1G (0.45) | CACNA1GCACNA1BCACNA1CSSTR4 | |
| SCHEMBL1732261 | 0.69 | LCK (0.37) | — | |
| SCHEMBL16057149 | 0.69 | CACNA1G (0.41) | CACNA1GCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3286172-A1 | LSD1 INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172496-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | GRM2 832/4885CACNA1G 2303/4885CACNA1B 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.